Congo's Ebola Crisis: 1,000 Cases in Two Weeks, No Vaccine, and a Response That Can't Keep Up

On May 30, 2026, WHO Director-General Tedros Adhanom Ghebreyesus landed in Bunia, the capital of Ituri Province in northeastern Democratic Republic of the Congo, at the epicenter of an Ebola outbreak that has outrun every tool available to contain it [1]. The visit came as Médecins Sans Frontières warned that "never before has an Ebola outbreak recorded so many cases so soon after its declaration" [2]. Within hours of his arrival, official figures crossed a threshold: more than 1,000 suspected cases and at least 220 deaths, with confirmed cases nearly doubling from 121 to 225 in just two days [3].

The crisis is compounded by a fact that distinguishes it from every recent Ebola emergency: this outbreak is caused by the Bundibugyo ebolavirus, a rare strain for which no approved vaccine or therapeutic exists [4]. The tools that helped contain the 2018–2020 Kivu epidemic — Merck's Ervebo vaccine, monoclonal antibody treatments — were designed for the Zaire ebolavirus and do not work against Bundibugyo [5].

The Numbers: A Trajectory Without Precedent

Source: WHO / DRC Ministry of Health

Data as of May 30, 2026CSV

The scale of this outbreak has surprised even experienced epidemiologists. The DRC Ministry of Health declared the outbreak on May 15, 2026, reporting 246 suspected cases and 80 deaths across three health zones: Bunia, Rwampara, and Mongbwalu [6]. By May 27, suspected cases had reached 906 with 223 deaths [1]. By May 30, the count exceeded 1,028 suspected cases [3].

That trajectory dwarfs the early weeks of the 2018–2020 Kivu outbreak, which — despite eventually killing more than 2,200 people and infecting 3,470 over nearly two years — took eight months to reach 1,000 cases [7]. The current outbreak reached that number in approximately two weeks.

The case fatality rate among suspected cases sits at roughly 21%, though this figure is unreliable. As MSF noted, "hundreds of samples remain untested," meaning the true number of infections and deaths is unknown [2]. Historically, Bundibugyo virus disease has carried a fatality rate between 30% and 50% [4]. The gap between the observed and historical rates may reflect undercounting of deaths, an influx of milder suspected cases that will test negative, or both.

The outbreak has also crossed international borders. Uganda confirmed nine cases and one death by May 30, with at least three cases linked to travel from DRC [8]. Cases have been confirmed in DRC's Ituri, North Kivu, and South Kivu provinces, with a case in South Kivu reportedly imported from Tshopo Province [4].

PHEIC: An Extraordinary Declaration

On May 17, just two days after the outbreak's official declaration, WHO designated it a Public Health Emergency of International Concern — the organization's highest alert level [6]. Tedros made the declaration before convening an Emergency Committee, a step he acknowledged was unusual but justified by the "extraordinary" circumstances: a high positivity rate among initial samples (eight of 13), confirmed international spread to Uganda, and the absence of any medical countermeasure [6].

The Emergency Committee met on May 19 and issued temporary recommendations to all member states, including enhanced surveillance at borders and preparation of health facilities [9]. The committee also recommended against general travel and trade restrictions, though Uganda and Rwanda moved ahead with border measures regardless. Uganda closed its border with DRC for at least four weeks, requiring 21-day isolation for anyone entering from the DRC [10]. Rwanda introduced mandatory quarantine for travelers returning from DRC on May 22 [10].

Tedros, during his visit to Bunia, urged countries to reconsider such measures, arguing they "discourage transparency" and may push cross-border movement underground rather than stopping it [1].

The Vaccine Gap: Months, Not Weeks

The single most consequential difference between this outbreak and its predecessors is the absence of a vaccine. The Ervebo (rVSV-ZEBOV) vaccine, which demonstrated high efficacy through ring vaccination during the 2018–2020 Kivu outbreak, targets the Zaire ebolavirus and is not approved for Bundibugyo [5].

On May 28, WHO convened independent experts to evaluate candidate treatments and vaccines. Their findings underscored the timeline problem [11]:

• ChAdOx1 Bundibugyo, developed by Oxford University and the Serum Institute of India, is the nearest candidate but still requires additional animal data. It could reach clinical trial readiness in two to three months — meaning it would not be available for use in the current outbreak's most critical window [11].
• rVSV Bundibugyo, being developed by the International AIDS Vaccine Initiative using the same platform as Ervebo, is considered the most promising long-term candidate but is at least seven to nine months from clinical trials [11].
• Ervebo itself is available from global stockpiles — roughly 145,690 doses have been shipped from the ICG stockpile since 2021 — but WHO recommended its use only within research protocols, not as a standard intervention, given the lack of evidence for cross-strain protection [5][11].

For treatment, the experts prioritized three candidates for clinical evaluation: the monoclonal antibodies MBP134 and Maftivimab, and the antiviral remdesivir. An oral antiviral, obeldesivir, was recommended for post-exposure prophylaxis among contacts of confirmed cases [11]. All of these remain experimental. WHO emphasized that every product should be used "exclusively within clinical trials" [11].

The practical implication: containment must rely entirely on non-pharmaceutical measures — surveillance, contact tracing, isolation, and safe burials — in a region where each of those activities faces severe obstacles.

"Cases Outpacing Response": What the Numbers Show

MSF's characterization of the response falling behind is supported by specific operational gaps. UNICEF has deployed 1,300 health workers and 100 motorbikes for contact tracing [12]. WHO and the DRC Ministry of Health have deployed more than 35 experts and first responders [13]. But the ratio of contact tracers to confirmed cases — a standard metric for Ebola containment — appears far below what was achieved in past outbreaks.

During the 2018–2020 Kivu response, MSF alone employed nearly 4,000 local medical staff and more than 325 international staff for treatment, surveillance, contact tracing, health promotion, and psychological support [14]. The current deployment is a fraction of that scale, despite a faster-growing caseload.

The DRC Ministry of Health reported 156 high-risk contacts identified through contact tracing, with 89% under daily monitoring [12]. For an outbreak with 225 confirmed cases and over 1,000 suspected cases, 156 identified high-risk contacts is a strikingly low figure. During the West Africa epidemic, the WHO target was at least 20 contacts traced and monitored per confirmed case to achieve containment [15]. By that standard, current contact tracing covers a small fraction of the needed population.

MSF stated bluntly: "The reality today is that nobody knows the true scale and severity of this outbreak. New suspected cases are being reported daily, yet hundreds of samples remain untested" [2].

The Security Bottleneck

Ituri Province is one of the most dangerous places on Earth for humanitarian operations. Armed groups — including the Allied Democratic Forces (ADF, aligned with the Islamic State), the Coopérative pour le développement du Congo (CODECO), and the Rwanda-backed M23 — control significant territory across eastern DRC [16]. The DRC has more than 5.1 million internally displaced persons, the fourth-highest total globally [17].

Source: UNHCR Population Data

Data as of Dec 31, 2025CSV

The consequences for the Ebola response have been direct and violent. Within one week, three major attacks on health facilities were documented [18]:

• Armed men stormed a hospital treating Ebola patients, forcing medical staff to evacuate under gunfire.
• Residents in Mongbwalu set fire to an MSF facility housing suspected and confirmed cases; more than a dozen patients fled.
• A treatment center in Rwampara was burned after relatives were prevented from retrieving a suspected victim's body for traditional burial.

A Congolese doctor died in Rwampara. Three Red Cross volunteers died in Mongbwalu after handling suspected bodies. In Uganda, three health workers were infected [18].

Beyond targeted attacks, the geography of the conflict zone creates a logistical chokepoint. Travel between Bunia and Mongbwalu — two key outbreak areas — spans more than 1,000 kilometers through rebel-controlled territory. A major humanitarian airport has been under rebel control for over a year, limiting the movement of testing equipment and response personnel [18].

Tedros acknowledged the conditions directly: the outbreak was spreading in an environment where "insecurity, attacks on health facilities and population movements" make it "nearly impossible" to trace contacts and isolate cases [16].

No concrete security arrangements with armed factions have been publicly reported to guarantee sustained humanitarian access.

Community Resistance and the Trust Deficit

The attacks on health facilities are not solely the work of armed groups. Community resistance — rooted in deep distrust of outside interventions — has emerged as a distinct obstacle. Residents in Bunia pelted health workers with stones [18]. One resident told NPR: "These people should stop bothering us. They just want to get rich. Let's not forget that Ebola is a white man's invention" [18].

This hostility echoes patterns from the 2018–2020 Kivu outbreak, where attacks on Ebola treatment centers were frequent and contributed to the outbreak's prolonged duration. The distrust has multiple roots: decades of conflict and state neglect, past experiences with international organizations that brought resources but left local health systems largely unchanged, and burial customs that conflict with infection control protocols.

Tedros framed community engagement as the center of any successful response: "The communities understand the problems better, and they know the solution" [1]. Whether that framing translates into operational changes — as opposed to the top-down containment model that has defined most Ebola responses — remains to be seen.

Funding: Who Pays, and Is It Enough?

Source: WHO / World Bank / State Dept

Data as of May 30, 2026CSV

International donors have mobilized significant funding, though the total falls short of what past outbreaks have required. The Africa Centers for Disease Control and Prevention reported $500 million in pledges [3]. The United States committed $112 million in bilateral assistance, including funding for up to 50 treatment clinics [19]. The World Bank is drawing on existing projects — including a $555 million nutrition and health project already operating across 3,500 health facilities — and "actively exploring" additional financing through its Crisis Response Toolkit and the Pandemic Fund [20]. WHO released $3.9 million from its Contingency Fund for Emergencies. The Intergovernmental Authority on Development (IGAD) redirected approximately $7 million toward regional prevention [3]. The European Union sent medical supplies to Ituri [3].

But the broader funding picture is concerning. Global health emergency funding declined from $498 million to $219 million — a reduction exceeding 50% — in the period preceding this outbreak [3]. The withdrawal of United States funding for global health programs in 2025 was cited as a contributing factor to the DRC health system's weakened capacity to respond [13].

The DRC government's own financial commitment to the response has not been publicly detailed. This opacity complicates accountability: it is unclear which organizations control disbursement of emergency funds and what oversight mechanisms are in place. During the 2018–2020 Kivu outbreak, WHO itself faced an internal investigation into financial mismanagement of Ebola response funds, a history that hangs over current funding discussions.

The Counter-Argument: Do Large External Deployments Work?

Not all public health experts agree that a massive international deployment is the right prescription. A body of research on past DRC Ebola responses suggests the relationship between external scale-up and outbreak duration is not straightforward.

The 2018–2020 Kivu outbreak saw the largest Ebola response in history — thousands of international personnel, hundreds of millions in funding — yet lasted nearly two years [7]. By contrast, several smaller DRC outbreaks (the country's 11th through 16th) were contained in weeks or months with primarily local response capacity and targeted international support [15].

Critics of the "emergency international response" framing argue that large deployments can overwhelm local health infrastructure, create parallel systems that collapse when international organizations leave, and generate resentment that fuels the very community resistance now being documented. The World Bank's investment in laboratory infrastructure — including the largest biosafety-level laboratory in eastern DRC, now serving as the central testing hub — represents an alternative model that builds durable local capacity [20].

The strongest case for large-scale international intervention rests on the unique features of this outbreak: a strain with no vaccine, a faster trajectory than any predecessor, and confirmed international spread. These factors may argue for a response calibrated differently from past outbreaks, while drawing on lessons about what did and did not work.

Cross-Border Risk: Rwanda, Uganda, and Beyond

The outbreak has already crossed into Uganda, where nine cases and one death have been confirmed [8]. Uganda's response included border closure, 21-day mandatory isolation for arrivals from DRC, and activation of surveillance and screening systems [10]. Rwanda introduced mandatory quarantine for DRC travelers on May 22 [10].

These measures carry significant economic costs for border communities that depend on cross-border trade. Tedros argued that such restrictions can be counterproductive, driving movement through informal crossings where no screening occurs [1]. The WHO Emergency Committee's temporary recommendations explicitly advised against general travel and trade restrictions [9].

The risk of further spread is driven by structural factors: high population mobility in the Great Lakes region, extensive informal cross-border movement linked to mining and trade, displaced populations living in camps near international borders, and the presence of cases in major urban centers including Bunia and Kampala [6][10]. If the outbreak is not contained within the coming months, neighboring Burundi — which shares a border with South Kivu, one of the affected provinces — faces exposure risk, as does the broader East African Community through air travel from Kampala.

What Happens Next

The next 90 days will determine whether this outbreak follows the trajectory of a contained emergency or becomes a prolonged regional crisis. Three factors will be decisive:

Testing capacity. With hundreds of samples untested, the true scope of the outbreak remains unknown. The World Bank-financed biosafety-level laboratory in eastern DRC is operational, but sample collection and transport across conflict zones remain the binding constraint [20][2].

Candidate therapeutics. If clinical trials of MBP134, Maftivimab, or remdesivir can be launched quickly and show efficacy, they would represent the first treatment option for Bundibugyo virus disease. The ChAdOx1 vaccine is the nearest prevention candidate, but two to three months is an eternity in an outbreak growing this fast [11].

Security and access. Without negotiated humanitarian corridors through rebel-held territory, the response cannot reach the populations most at risk. The failure to secure the humanitarian airport near the outbreak zone is a concrete bottleneck that, unlike vaccine development, could theoretically be addressed through diplomatic or military action [18].

Tedros told communities in Bunia: "You are not alone in this. We are here, we are with you" [1]. The gap between that promise and the operational reality on the ground — untested samples, burned treatment centers, armed groups blocking roads — is the central tension of this outbreak.